Interpretation: FibroTouch Liver Elastography Report
Patient: Mr. Anuj, Male, 28 yrs | Height 164 cm, Weight 70 kg, BMI 26.0 (overweight) | Referring: Dr. Vishal Garg
Test quality — reliable
- Success rate: 100% (10/10 valid measurements)
- Stiffness IQR/Median: 7%, UAP IQR/Median: 11% — both well within the acceptable reliability threshold (<30%, ideally <10%). This is a technically good-quality scan, not just noise.
1. Liver stiffness (fibrosis) — Normal
- Median stiffness: 5.6 kPa, which falls in the F0-F1 band (<7.3 kPa) on the report's own reference scale.
- This means no significant liver fibrosis is detected. Transient elastography (the technology FibroTouch is based on) estimates fibrosis by measuring shear-wave propagation speed through the liver; values in this range are reassuring, well below the ~14 kPa threshold used to flag possible cirrhosis - Sleisenger and Fordtran's Gastrointestinal and Liver Disease.
2. UAP (steatosis / fatty liver) — Moderate
- Median UAP: 273 dB/m, which falls in the "Moderate" band (265-295 dB/m) on the report's scale (Normal <240, Mild 240-265, Moderate 265-295, Severe >295).
- UAP works like the CAP (controlled attenuation parameter) used in FibroScan - it estimates the degree of fat infiltration in the liver by measuring ultrasound signal attenuation. A value of 273 indicates moderate hepatic steatosis (fatty liver).
Overall picture
This is a classic early pattern of metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): moderate fat deposition in the liver (elevated UAP) with no fibrosis yet (normal stiffness, F0-F1). The overweight BMI (26.0) fits with this metabolic picture.
What this means practically:
- The liver is not currently scarred/fibrotic — a good sign.
- There is moderate fat buildup that, left unaddressed, can progress over years toward steatohepatitis and eventual fibrosis.
- Standard next steps typically recommended by physicians in this situation: weight reduction (5-10% body weight), dietary modification, regular exercise, and checking liver enzymes (ALT/AST), fasting glucose/HbA1c, and lipid profile to rule out associated metabolic syndrome/diabetes. Alcohol intake history is also relevant since UAP does not distinguish alcoholic from non-alcoholic causes of steatosis.
The report itself notes these values are "for reference only" — the treating physician (Dr. Vishal Garg) should correlate this with clinical history and bloodwork for a formal diagnosis and management plan. This interpretation is educational and not a substitute for that clinical correlation.
Recent evidence check: A 2026 systematic review (PMID: 40451522) and a 2024 meta-analysis (PMID: 38685902) on liver stiffness/steatosis measures in MASLD support that low LSM values (as seen here) reliably predict absence of advanced fibrosis, consistent with this interpretation - no contradiction found.